Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Carboxymaltose vs Iron Sucrose for Functional Iron Deficiency in Surgical ICU
NCT02009943Phase 1Withdrawn
- Sponsor
- Denver Health
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric carboxymaltose in Functional iron deficiency (FID) and anemia, sponsored by Denver Health. Primary endpoint: Transferrin Saturation at 1 week. Planned start Feb 2017; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
Functional iron deficiency (FID)anemia
Beyond the preview
Go deeper on NCT02009943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009943.